Richard Osbourne

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Janet E. Brown, Kara‐Louise Royle, Walter M. Gregory et al. · The Lancet Oncology · 2023 · 81 citations · Full text

Medicine, Oncology, Pharmacology +11

Implementation of the Australasian Teletrial Model: Lessons from practice

John Zalcberg, Craig Underhill, Rob Zielinski et al. · Asia-Pacific Journal of Clinical Oncology · 2019 · 21 citations · Full text

Law, Decision Sciences, Health Technology Assessment +6

Difficulty with Life and Death: Methodological Issues and Results from the Utility Scaling of the Assessment of Quality of Life (AQoL) Instrument

Jeff Richardson, Graeme Hawthorne, Neil Day et al. · Figshare · 2017 · 13 citations

Pharmacy, Internal Medicine, Health Assessment +13

The Australian Multi-attribute Utility (AMAU) construction and Initial Evaluation

Graeme Hawthorne, Richard Osbourne, Helen McNeil et al. · Figshare · 2017 · 13 citations

Pharmacy, Educational Measurement, Cost-utility Analysis +16